Skip to main content
Glama

Imf Portwatch

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the annotations (readOnly, openWorld, idempotent), the description discloses real behavioral semantics: 'sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug', that private companies return 'resolved:false with an explicit notes line', and that small-molecule-only companies correctly show no fda_products. These are exactly the edge-case behaviors that could confuse an agent without reading this text.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but front-loaded with trigger examples and the central 'ALWAYS PREFER' instruction. It is organized as a single dense paragraph, with slight redundancy between the query examples and the later 'Pass a ticker...' sentence. Each sentence adds value, but it could be trimmed without losing meaning, so not a perfect 5.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema, the description unusually thoroughly covers the returned sections (cik, recent_filings, fundamentals, patents, contracts, fda_products, hiring, news, LEI), the meaning of empty sections, resolved metadata, and fallback behavior. It also covers input variants and the private-company edge case. Nothing critical is missing for an agent to call it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although schema coverage is 100%, the description greatly enriches the parameters: 'type accepts company or ticker interchangeably', 'value' can be a ticker, zero-padded CIK, or name, and names 'resolve via SEC EDGAR's company-name match'. The private-company behavior further explains the outcome of valid inputs.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with many concrete trigger phrases ("Tell me about X", "brief me on Tesla") and then states the core function: 'full cross-source profile of a US public company in ONE parallel call.' It enumerates the specific sources (SEC EDGAR, XBRL, USPTO, USAspending, Purple Book, DOL LCA, news, GLEIF), making the tool's purpose unmistakable and distinct from siblings like resolve_entity or search_within.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives an explicit routing instruction: 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view.' This tells the agent exactly when to choose this tool and what it should be preferred over. The input examples (ticker, CIK, name) further clarify how to invoke it.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Imf Portwatch toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.2/5.0
Disambiguation4/5

Most tools have clear distinct purposes, but the three ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) are very similar, and there is some overlap between bet_research and polymarket_edges. Overall, the majority are well-differentiated.

Naming Consistency5/5

Tool names follow a consistent snake_case verb_noun pattern with only minor deviations (e.g., 'chokepoints_list' vs 'chokepoint_daily_traffic'). The naming convention is predictable and clear.

Tool Count2/5

At 37 tools, the surface is overly large for a focused server. Many tools are meta-tools that could have been consolidated, and the count exceeds the recommended range (25+), making it feel heavy and unwieldy.

Completeness5/5

The server covers maritime chokepoints comprehensively (list, status, daily, compare, disruptions), and the Pipeworx-based tools provide broad coverage across financial, drug, prediction market, and general query domains. There are no obvious gaps for the stated scope.

Resources